Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report
Clinical Transplantation · 2026-06 · 40 (6)
DOI: 10.1111/ctr.70587 ↗At a glance
Journal article in Clinical Transplantation, published online on 2026-06-12. Written by Alex Ng and 6 co-authors. Institution: Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Major MEDLINE topics: Alemtuzumab, Kidney Transplantation, Graft Survival, Graft Rejection. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Introduction
The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups.
Methods
Single‐center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30–49/50–69/70 years). All patients received a single 30‐mg intra‐operative dose of alemtuzumab. Standardized management algorithms were used. All patients received triple maintenance immunosuppression with tacrolimus/mycophenolate/steroids.
Results
From September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient ( p < 0.001) and graft ( p < 0.001) but not death‐censored graft survival ( p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy‐proven acute rejection, and infectious complications at 1‐year post‐transplant were comparable amongst groups.
Conclusion
In DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short‐term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
- Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Internal Medicine, Section of Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID profiles: Alex Ng, David I Harriman, Alan C Farney, Giuseppe Orlando, Colleen Jay, Robert J Stratta
Cite
APA
Ng, A., Harriman, D. I., Farney, A. C., Orlando, G., Jay, C., Reeves-Daniel, A., & Stratta, R. J. (2026). Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70587
Vancouver
Ng A, Harriman DI, Farney AC, Orlando G, Jay C, Reeves-Daniel A, et al. Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70587
BibTeX
@article{Ng2026,
author = {Ng, Alex and Harriman, David I and Farney, Alan C and Orlando, Giuseppe and Jay, Colleen and Reeves-Daniel, Amber and Stratta, Robert J},
title = {Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {6},
doi = {10.1111/ctr.70587}
}
EUVIMED